Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study

Table 5 Peak and mean uNGAL concentrations in survivors and nonsurvivors, by pRIFLEmax AKI strata

Measurement (ng/mg creatinine)	Group (numbers of patients: survivors/nonsurvivors)
	Control (31/3)	pRIFLEmax R (46/4)	pRIFLEmax I (25/6)	pRIFLEmax F (18/7)
Peak uNGAL^a
Survivors	0.6 ± 1.8/0.1 (0.4)	0.9 ± 1.4/0.4 (1.2)	2.4 ± 3.5/0.8 (2.0)	4.1 ± 3.7/2.7 (5.5)
Nonsurvivors	0.4 ± 0.3/0.2 (0.5)	1.8 ± 2.7/0.7 (3.2)	2.7 ± 5.0/0.9 (1.0)	2.8 ± 4.0/1.5 (1.8)
Mean uNGAL^a,b
Survivors	0.4 ± 1.3/0.1 (0.2)	0.6 ± 0.8/0.3 (0.7)	1.6 ± 2.5/0.5 (1.8)	3.1 ± 3.1/2.2 (4.2)
Nonsurvivors	0.3± 0.2/0.2 (0.4)	1.1 ± 1.5/0.6 (2.1)	1.8 ± 3.0/1.0 (1.1)	1.9 ± 2.6/1.1 (1.1)

Values are expressed as mean ± standard deviation/median (interquartile range). ^aPeak and mean urine neutrophil gelatinase-associated lipocalin (uNGAL) concentrations were not statistically significantly different between survivors and nonsurvivors in any of the pRIFLE strata (P > 0.05, Mann-Whitney test). ^bMean uNGAL refers to the mean of all 4 urine specimens collected for each patient. pRIFLEmax, the worst pRIFLE stratum attained; pRIFLE, pediatric modified Risk, Injury, Failure, Loss, End Stage Kidney Disease.

ISSN: 1364-8535